Table 1 Aspirin use and lung cancer risk – summary of published studies.
Study (reference) | Year (place) | Design | Study sample | Key results |
|---|---|---|---|---|
Peto et al.[17] | 1988 (UK) | Randomized Trial | 5139 British physicians: aspirin intervention group (n = 3429) vs. placebo group (n = 1710) | Lung cancer death rates lower in aspirin group (7.4/10.000 person years) vs. placebo group (11.6/10.000 person years) |
Paganini-Hill et al.[18] | 1989 (US) | Cohort study | 13 987 retirement community residents; 111 lung cancer cases after 6.5 years of follow-up | No evidence of lower incidence of lung cancer among male daily aspirin users (RR = 1.35); Lower incidence of lung cancer among female daily aspirin users (RR = 0.29) |
Thun et al.[19] | 1993 (US) | Cohort study | Cancer Prevention Study II: 635,031 US residents; 6 year follow-up | No evidence of lower mortality from respiratory cancers in association with aspirin use among men; Lower respiratory cancer mortality among women using aspirin 1–15 times/month (RR = 0.73; 95 % CI 0.56–0.97) |
Schreinemachers & Everson [14] | 1994 (US) | Cohort study | NHANES I follow-up: 12,668 US residents; 189 respiratory cancers after 12.4 years (mean) of follow-up | Significantly lower incidence of lung cancer among men using aspirin in past 30 days (RR = 0.55; 95% CI 0.38–0.81); No evidence of lower lung cancer incidence among women using aspirin (RR = 1.40; 95% CI 0.74–2.66) |
Rosenberg[20] | 1995 (US) | Hospital-based case-control study | 1110 lung cancer cases; 1181 cancer controls and 4906 non-cancer controls | Non-significant risk reduction associated with aspirin use when case group compared to cancer controls (RR = 0.80; 95% CI 0.60–1.20), but not apparent when compared to non-cancer controls (RR = 1.00; 95% CI 0.70–1.40) |
Langman[21] | 2000 (UK) | Record-linkage case control study | 2560 lung cancer patients and 7643 controls identified from general practice research data base | Non-significant risk reduction associated with 7+ prescriptions of NSAIDs 1–3 years prior to diagnosis (OR = 0.84; 95% CI 0.69–1.02) |
Akhmedkhanov et al.[22] | 2002 (US) | Nested case-control study | 81 female lung cancer patients and 808 controls selected from the NYU Women's Health Study | Non significant risk reduction between regular aspirin use and overall lung cancer (OR = 0.66; 95% CI 0.34–1.28); Significant risk reduction between regular use and non-small cell carcinoma of the lung (OR = 0.39; 95% CI 0.16–0.96) |
Harris et al [23] | 2002 (US) | Case-control study | 489 lung cancer patients and 978 screening clinic controls (heavy smokers) | Significant risk reduction among daily aspirin users (OR = 0.32; 95% CI 0.23–0.44); effect seen among men and women |
Current study | 2002 (US) | Hospital-based case-control study | 868 lung cancer cases and 935 hospital controls with non-neoplastic conditions | Significant risk reduction among regular aspirin users (OR = 0.57; 95% CI 0.41–0.78); effect seen among men and women |